MIT engineers developed a new way to amplify the T cell response to mRNA vaccines, using an mRNA adjuvant. This approach could lead to much more powerful cancer vaccines and stronger protection ...
Investigational New Drug application for KHN921 received 'study may proceed” from the US FDA. KHN921 is a potential 'first-in-class' cardiovascular AAV gene therapy being developed for the treatment o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results